Stem Cell Therapeutics Corp. Provides Update on Market Activity

Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) announces today, at the
request of Investment Industry Regulatory Organization of Canada (IIROC) on
behalf of the TSX Venture Exchange, that it is not aware of any corporate
developments to account for the recent trading activity in SCT's stock.


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian
public biotechnology company (TSX VENTURE:SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. SCT is a leader in the development of therapies that utilize drugs to
stimulate a patient's own resident stem cells. The Company's programs aim to
repair neurological function lost due to disease or injury. SCT's extensive
patent portfolio of owned and licensed intellectual property supports the
potential expansion into future clinical programs in numerous neurological
diseases such as traumatic brain injury, multiple sclerosis, Huntington's
disease, Alzheimer's disease, ALS.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available.


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.